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Dear Editor, 
 
Bladder cancer is one of the most common cancers in men and the 15th most common 
cancer in European women (Ferlay et al., 2013). Though the prognosis for non-muscle inva-
sive tumours is generally good, a major problem are the frequent relapses (30-80 %) and the 
risk of progression to muscle invasive tumours (van Rhijn et al., 2009). Development of blad-
der cancer can be attributed mostly to tobacco smoke and occupational as well as to a genetic 
predisposition (Brennan et al., 2000; Golka et al., 2002, 2004; Boffetta, 2008; Rushton et al., 
2012; Schwender et al., 2012; Bolt, 2013a, b; Burger et al., 2013; Egbers et al., 2014). Po-
lymorphisms of phase II metabolizing enzymes are well-known since many years to modulate 
bladder cancer risk, in particular, in presence of exposure to bladder carcinogens (Garcia-
Closas et al., 2005; Moore et al., 2011). The impact of the deletion variant of glutathione-S-
transferase M1 (GSTM1) (Arand et al., 1996; Golka et al., 1997, 2008; 2009; Ovsiannikov et 
al., 2012) and the polymorphic N-acetyltransferase 2 (NAT2) gene (Garcia-Closas et al., 
2005; Golka et al., 1996, 2002; Rothman et al., 2010; Moore et al., 2011; Selinski et al., 2011, 
2013a, 2013b, 2014; Blaszkewicz, 2013) is well understood. Since 2008 large genome-wide 
association studies (GWAS) have discovered a panel of further moderate risk polymorphisms 
located in twelve regions across the genome (Selinski, 2014b). However, the functional role 
of these variants is still not clear for most of them (Grotenhuis et al., 2010; Golka et al., 2011; 
Selinski, 2012, 2013, 2014b; Dudek et al., 2013). Current studies aim to investigate common 
effects of variants and their interaction with exposure to bladder carcinogens (Schwender et 
al., 2012; Hammad, 2013; Selinski, 2014a). However, the impact of genetic risk factors on 
recurrence, progression and survival is poorly understood and a genome-wide search for 
prognostic polymorphisms is still lacking.  
Most studies concentrate on the impact of glutathione S-transferases (GST), mainly 
GSTM1 and GSTT1, or on other polymorphic candidate genes. Besides overall survival, often 
restricted to the subgroup of muscle invasive bladder cancer (MIBC) patients, relapse- and 
progression-free survival in non-muscle invasive bladder cancer (NMIBC) cases is of main 
interest due to the high recurrence risk.  
Studies on the GST polymorphisms show a wide range of positive and negative findings 
requiring larger studies and careful meta-analyses. In particular, polymorphic GSTs might be 
relevant in patient subgroups (Kang et al., 2014). Recent studies show the following results: 
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 GSTT1 positive genotypes were associated with a shorter recurrence and progression free 
survival time (Ha et al., 2010). 
 GSTM1 negative tumor tissues were associated with shorter recurrence free survival in 
NMIBC patients (Ha et al., 2011).  
 GSTM1 negative bladder cancer patients from the Copenhagen City Heart Study had a de-
creased 5-year survival (Nørskov et al., 2011). 
 GSTT1 null genotype was associated with shorter recurrence-free survival time. No asso-
ciation was found in case of GSTM1, NAT2, and the GWAS SNPs rs710521 (TP63) and 
rs9642880 (MYC) (Roth et al., 2012). 
 Polymorphic GSTT1, GSTO1 and GSTO2 were associated with overall survival. No asso-
ciation with survival was found in case of GSTP1, GSTM1 and GSTA1 (Djukic et al., 
2013). 
 GSTT1 null genotype was associated with disease progression and shorter survival time in 
MIBC cases (Kang et al., 2013). 
 GSTT1 positive genotype was associated with shorter survival time and BCG therapy fail-
ure in NMIBC patients (Kang et al., 2014). 
 
A number of recent studies concentrate on polymorphisms in selected candidate genes. 
Validation by an independent research group is still lacking though the authors often replicat-
ed their findings in further study groups. Candidate genes are usually cancer-related but also 
miRNA polymorphisms. 
 miR-146a SNP rs2910164 was associated with bladder cancer risk and recurrence in a 
large Chinese study (Wang et al., 2012). 
 In a study of miRNA biogenesis genes DDX20 (DEAD (Asp-Glu-Ala-Asp) box polypep-
tide 20) missense SNP rs197412 was associated with longer recurrence-free survival in 
NMIBC patients. Two DGCR8 (DGCR8 microprocessor complex subunit) SNPs 
rs2073778 and rs720012 were associated with tumor progression (Ke et al., 2013). 
 In a study of regulator of G-protein signaling (RGS) gene variants RGS5 (regulator of G-
protein signaling 5) intron SNP rs2344673 was associated with survival in MIBC patients. 
Rs1323291, rs3795617 and rs16829458 were associated with risk of recurrence in 
NMIBC patients. Rs1323291, rs10917690, rs6678136 and rs11585883 were associated 
with risk of progression from NMIBC to MIBC (Lee et al., 2013).  
 TERT (telomerase reverse transcriptase) promotor mutations were associated with surviv-
al and recurrence (Rachakonda et al., 2013). 
 Five SNPs in the XRCC1 (X-ray repair complementing defective repair in Chinese ham-
ster cells 1) repair gene were associated with better survival (Sacerdote et al., 2013). 
 TSP-1 (thrombospondin-1) SNP rs2169830 was associated with recurrence time and TSP-
1 mRNA expression (Yang et al., 2013). 
 The largest study so far on candidate SNPs was just published by Andrew et al. (2014) 
investigating the association of 1367 SNPs from about 400 potentially cancer-related 
genes, e. g. from apoptosis, proliferation, DNA repair, hormone regulation, immune sur-
veillance, and cellular metabolism pathways. ALDH2 (aldehyde dehydrogenase 2 family 
(mitochondrial)) SNP rs2238151 and IGF1 (insulin-like growth factor 1 (somatomedin 
C)) SNP rs5742714 were associated with a shorter recurrence-free time. XRCC4 (X-ray 
repair complementing defective repair in Chinese hamster cells 4) SNP rs2662238, DRD4 
(dopamine receptor D4) SNP rs4987059 and RB1CC1 (RB1-inducible coiled-coil 1) SNP 
rs35402311 were associated with overall survival in NMIBC patients (Andrew et al., 
2014). 
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So far, only one study investigated the complete panel of candidate variants from GWAS.  
 Grotenhuis et al. (2014) investigated twelve confirmed bladder cancer polymorphisms 
with regard to recurrence and progression in NMIBC patients and to overall survival in 
MIBC patients. The MYC near SNP rs9642880 was associated with progression-free but 
not with recurrence-free survival in NMIBC patients or with overall survival in MIBC 
cases. The TACC3-FGFR3 (transforming, acidic coiled-coil containing protein 3 - fibro-
blast growth factor receptor 3) SNP rs798766 was associated with recurrence-free surviv-
al in non-smoking NMIBC cases. The NAT2 tagSNP rs1495741 was associated with re-
currence in ever smoking NMIBC cases and progression-free survival in non-smoking 
NMIBC cases. No association with recurrence- or progression-free survival or with over-
all survival was found in case of the GSTM1 deletion, the UGT1A (UDP glucuronosyl-
transferase 1 family, polypeptide A6) SNPs rs11892031 and rs17863783, TP63 (tumor 
protein p63) near rs710521, the CLPTM1L-TERT (CLPTM1-like  telomerase reverse tran-
scriptase) SNPs rs401681 and rs2736098, the PSCA (prostate stem cell antigen) SNPs 
rs2294008 and rs2978974, rs1058396 (SLC14A1, solute carrier family 14 (urea trans-
porter), member 1), rs8102137 (CCNE1, cyclin E1) and rs1014971 (CBX6-APOBEC3A, 
chromobox homolog 6 - apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3A) (Grotenhuis et al., 2014).  
 
Most of the studies comprise more than 200 cases similar to the validation case-controls 
series in the GWAS. Thus, reasonable validation case groups are available and special em-
phasis should be placed on a systematic genome-wide search for prognostic variants. 
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